Health benefit: Glucose regulation

Blood glucose regulation: a key factor in health

Chronic hyperglycemia leads to oxidative stress, cellular damage, and persistent inflammation.
Maintaining stable blood glucose levels, particularly through the management of oxidative stress, is essential to prevent or delay the development of type 2 diabetes.

6.7% of the global population is affected by diabetes. Type 2 diabetes accounts for 90% of all diabetes cases¹

By 2050, the number of people living with diabetes could reach 3 billion worldwide¹.

Each year, 5 to 10% of individuals with prediabetes progress to type 2 diabetes¹.

Why is blood glucose control crucial?

Prolonged glycemic imbalance can lead to:

Dysfunction of pancreatic β‑cells, reducing insulin production
Impaired glucose metabolism, resulting in elevated blood glucose levels
Increased oxidative stress, causing cellular damage—particularly to β‑cells—and promoting chronic inflammation

This complex interplay between hyperglycemia, oxidative stress, and chronic inflammation contributes significantly to the development of type 2 diabetes as well as its associated complications.²

It has been clinically demonstrated that under hyperglycemic conditions, activation of the Nrf2 pathway may play a role in reducing hyperglycemia and its associated effects.³

SULFODYNE® : a natural approach for blood glucose management

SULFODYNE® contains sulforaphane, a bioactive compound recognized for its ability to activate the Nrf2 pathway. Through this activation, it stimulates the body’s antioxidant defense mechanisms, helping to limit damage associated with hyperglycemia and the resulting inflammatory responses. Preclinical and clinical data indicate that sulforaphane plays a role in glucose regulation, supporting blood glucose management by mitigating oxidative stress and inflammation linked to hyperglycemic condition.

Blood glucose regulation

Restoration of normal pancreatic β‑cell function³
Reduction of insulin resistance⁴
Improved glucose uptake and transport into cells⁵
Stabilization of blood glucose levels⁵
Reduction of glucose production, with effects comparable to metformin⁵

Clinical study results in prediabetic and type 2 diabetic Individuals

- Clinical study in 97 patients with type 2 diabetes (T2D) receiving metformin
- Randomized, double‑blind, placebo‑controlled, parallel‑group study
- Equivalent to 26.6 mg of sulforaphane per day for 12 weeksClinical Trial in Type 2 Diabetes – 26.6 mg/day
- Reduction in fasting blood glucose⁵
- Decrease in glycated hemoglobin (HbA1c), a key marker of long‑term glycemic control⁵

Clinical Trial in Prediabetic Individuals – 26.6 mg/day
- Clinical study in 89 prediabetic adults
- Randomized, double‑blind, placebo‑controlled, parallel‑group study
- Equivalent to 26.6 mg of sulforaphane per day for 12 weeks
- Reduction in fasting blood glucose levels⁶
- Reduction in insulin resistance and HOMA‑IR index⁶
- Improvement in pancreatic β‑cell function and HOMA‑B index⁶

Clinical Trial in Type 2 Diabetes – 40 mg/day
- Clinical study in 81 adults with type 2 diabetes
- Equivalent to 40 mg of sulforaphane per day for 4 weeks
- Reduction in fasting blood glucose⁸
- Reduction in insulin resistance and HOMA‑IR index⁸

References :
1 : Diabetes Atlas IDF 10TH Edition, 2021 ; 2 : Gonzalez et al., 2023 ; 3 : Jiménez-Osorio et al., 2015 ; 4 : Nagata et al., 2017 ; 5 : Axelsson et al., 2017 ; 6 : Dwibedi et al., 2025 ; 7 : Connolly et al., 2025 ; 8 : Bahadoran et al., 2012 ; 9 :Saeidi et al., 2021